(Q46627529)

23 December 2017

title

Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits (English)

1 reference

23 December 2017

1 reference

1 reference

10

1 reference

23 December 2017

Louis Ignarro

9

object named as

Louis J Ignarro

1 reference

23 December 2017

1

Filomena de Nigris

1 reference

PubMed ID

18435936

retrieved

23 December 2017

Sharon Williams-Ignarro

6

object named as

Sharon Williams-Ignarro

1 reference

PubMed ID

18435936

retrieved

23 December 2017

Maria Luisa Balestrieri

object named as

Maria Luisa Balestrieri

3

0 references

author name string

Francesco Paolo Mancini

2

1 reference

23 December 2017

Russell Byrns

4

1 reference

23 December 2017

Carmela Fiorito

5

1 reference

23 December 2017

Antonio Palagiano

7

1 reference

23 December 2017

Ettore Crimi

8

1 reference

23 December 2017

publication date

4 April 2008

1 reference

23 December 2017

published in

Nitric Oxide

1 reference

23 December 2017

volume

19

1 reference

23 December 2017

issue

1

1 reference

23 December 2017

page(s)

57-63

1 reference

23 December 2017

Oxidation-sensitive mechanisms, vascular apoptosis and atherosclerosis

cites work

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Angiographic evolution of coronary atherosclerosis in patients receiving propranolol. A two-year follow-up

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

The pharmacology of carvedilol

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Use of nebivolol for the treatment of endothelial dysfunction in patients with hypertension: the EDEN registry

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Antioxidant activity of nebivolol in the rat aorta

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Nebivolol decreases systemic oxidative stress in healthy volunteers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Does the beta-blocker nebivolol increase coronary flow reserve?

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Dual effects of the antioxidant agents probucol and carvedilol on proliferative and fatty lesions in hypercholesterolemic rabbits

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Effect of vitamin E on atherogenesis in LDL receptor-deficient rabbits

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Nitric oxide and atherosclerosis: an update

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Nebivolol increases arterial distensibility in vivo.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Nebivolol Induces Endothelium Dependent Relaxatíons of Canine Coronary Arteries

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Nitric oxide as a signaling molecule in the vascular system: an overview.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Effects of a Pomegranate Fruit Extract rich in punicalagin on oxidation-sensitive genes and eNOS activity at sites of perturbed shear stress and atherogenesis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N'-diphenyl-phenylenediamine

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Nitric oxide and atherosclerosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Carvedilol inhibits aortic lipid deposition in the hypercholesterolemic rat.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide‐mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

New trends in anti-atherosclerotic agents.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Maternal hypercholesterolemia enhances atherogenesis in normocholesterolemic rabbits, which is inhibited by antioxidant or lipid-lowering intervention during pregnancy: an experimental model of atherogenic mechanisms in human fetuses

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Mildly Oxidized Low-Density Lipoprotein Impairs Responses of Carotid but Not Basilar Artery in Rabbits

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Nitric oxide-releasing drugs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Unique effect of nebivolol on coronary hemodynamics: it's all a matter of flow

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Nebivolol Prevents Vascular NOS III Uncoupling in Experimental Hyperlipidemia and Inhibits NADPH Oxidase Activity in Inflammatory Cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Maternal hypercholesterolemia and treatment during pregnancy influence the long-term progression of atherosclerosis in offspring of rabbits

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Nitrosylation. the prototypic redox-based signaling mechanism.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Estrogen receptor-mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NIOX.2008.03.004

Identifiers

DOI

10.1016/J.NIOX.2008.03.004

1 reference

23 December 2017

PubMed ID

18435936

1 reference

23 December 2017